• BPL Statement on Gammaplex Supply
• FDA Approves Bio Products Laboratory’s Gammaplex® 10% for Treatment of Primary immunodeficiency and Chronic Immune Thrombocytopenic Purpura
• Bio Products Laboratory Receives European Approval for Coagadex® (Human Coagulation Factor X)
• Bio Products Laboratory Announces Supply of COAGADEX® Now Available in the United States
• Press Release: Bio Products Laboratory Receives FDA approval for Coagadex® (Coagulation Factor X, Human) First-ever FDA-approved treatment for hereditary factor X deficiency
• Press Release: Gammaplex® Approved For Use In Pediatric Patients
• Press Release: FDA Accepts BPL’s Amended BLA Submission for Coagadex® (Coagulation Factor X, Human)
• Press Release: Bio Products Laboratory, Ltd. Announces Results from Phase III Registration Study of its Factor X Coagulation Product
• Bio Products Laboratory Inc. (BPL) announces NEW vial size of Gammaplex® for the treatment of Primary Immunodeficiency and Chronic Immune Thrombocytopenic Purpura
• Press Release: Change of name to BPL Holdings for Plasma Resources UK
• Press Release: BPL announces strong progress on the world’s first licensed Factor X product
• Press Release: Change of Ownership
• Parliamentary Year Book
• Press Release on Investment Request
• Approval Letter - Gammaplex
  09/17/2009